ATLPC0002790

ATLPC0002790 — ADMETatlas

Structure and chemistry interpretation

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

map backed

Parent-residue sequence

Residue string used for positional interpretation when available.

KRIVQRIKDFLR

HELM

Polymer notation for modified peptide representation when available.

KRIVQRIKDFLR{nt:C6H5-C≡C-CO}{ct:Amid}

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references2 references

Structure reference·

3D coordinates·PEPstrMOD predictionpredicted

PEPstrMOD prediction·reference selected·length 12 aa·confidence predicted

Link	Method	Confidence	Match
Open

Covalent topology & modificationsnone

No explicit topology annotation

No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.

Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.

5. Toxicity / Safety

What safety, toxicity, or tolerability evidence is attached?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

% hemolysis % cytotoxicity Cytotoxicity metric

Hemolysis, cytotoxicity, clinical adverse-event context, and nonclinical safety context.

Evidence interpretation

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

% hemolysis23 measurements · 23 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	0 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
2	5 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
3	0 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
4	< 5 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
5	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
6	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
7	< 5 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
8	100 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
9	5 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open
10	50 %	Comparable	Human erythrocytes · Human erythrocytes · human · RBC	Not specified	Open

1–10 / 23

Interpretation: Clinical and nonclinical context can guide interpretation, but it is not incidence, causality, or a comparable endpoint measurement.

Evidence landscape and measurement index

Evidence landscape

A cross-domain view of where evidence is concentrated, which interpretation layers dominate, and how traceable the measurements are.

ADMET domain

Comparable

Reported

Contextual

Exposure / Absorption

0 measurements

Distribution / Barrier

0 measurements

Metabolic & Proteolytic Stability

0 measurements

Excretion / Persistence

0 measurements

Toxicity / Safety

40 measurements

Endpoint distribution

Top evidence-bearing endpoint questions.

Hemolysis Percent Observation

Cytotoxicity Metric

Cytotoxicity Percent Observation

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Cell / safety model

Unspecified

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every measurement remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainLayerReferenceSpeciesMatrix

#	ADMET domain	Endpoint	Reported value	Evidence layer	Assay / model	Condition	Reference
1	Toxicity / Safety Safety	Hemolysis Percent Observation	0 %	Comparable	Human erythrocytes · human · RBC	Not specified	Open
2	Toxicity / Safety Safety	Cytotoxicity Percent Observation	60 %	Comparable	Murine macrophage cells J774A.1 · mouse	Not specified	Open
3	Toxicity / Safety Safety	Cytotoxicity Metric	> 256 μg/mL	Comparable	Mouse fibroblasts NIH 3T3 · mouse	Not specified	Open
4	Toxicity / Safety Safety	Hemolysis Percent Observation	0.6 %	Comparable	Rabbit erythrocytes · rabbit · RBC	Not specified	Open
5	Toxicity / Safety Safety	Hemolysis Percent Observation	5 %	Comparable	Human erythrocytes · human · RBC	Not specified	Open
6	Toxicity / Safety Safety	Cytotoxicity Metric	0.8 μg/mL	Comparable	Mouse fibroblasts NIH 3T3 · mouse	Not specified	Open
7	Toxicity / Safety Safety	Hemolysis Percent Observation	0 %	Comparable	Human erythrocytes · human · RBC	Not specified	Open
8	Toxicity / Safety Safety	Cytotoxicity Percent Observation	0 %	Comparable	Human keratinocytes HaCat · human	Not specified	Open
9	Toxicity / Safety Safety	Hemolysis Percent Observation	< 5 %	Comparable	Human erythrocytes · human · RBC	Not specified	Open
10	Toxicity / Safety Safety	Hemolysis Percent Observation	50 %	Comparable	Human erythrocytes · human · RBC	Not specified	Open

1–10 / 40

Identity & reference map

Summary9 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 9
Measurements: 40
ATL peptide ID: ATLPC0002790

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

40 / 40

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 40

Different notation

Reported notation does not resolve to the current display sequence.

0 / 40

Reference map9 of 9 shown

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
PubMed 32019109 Open	Safety Cytotoxicity Metric, Hemolysis Percent Observation	No reported alias KRIVQRIKDFLRexact	27 identity 27 evidence
PubMed 40056800 Open	Safety Cytotoxicity Percent Observation, Hemolysis Percent Observation	No reported alias KRIVQRIKDFLRexact	3 identity 3 evidence
PubMed 32948086 Open	Safety Cytotoxicity Percent Observation	No reported alias KRIVQRIKDFLRexact	2 identity 2 evidence
PubMed 38323312 Open	Safety Cytotoxicity Metric, Hemolysis Percent Observation	No reported alias KRIVQRIKDFLRexact	2 identity 2 evidence
PubMed 27907988 Open	Safety Cytotoxicity Metric, Hemolysis Percent Observation	No reported alias KRIVQRIKDFLRexact	2 identity 2 evidence
PubMed 24105706 Open	Safety Hemolysis Percent Observation	No reported alias KRIVQRIKDFLRexact	1 identity 1 evidence
PubMed 24307932 Open	Safety Hemolysis Percent Observation	No reported alias KRIVQRIKDFLRexact	1 identity 1 evidence
PubMed 18591279 Open	Safety Cytotoxicity Percent Observation	No reported alias KRIVQRIKDFLRexact	1 identity 1 evidence
PubMed 32153522 Open	Safety Hemolysis Percent Observation	No reported alias KRIVQRIKDFLRexact	1 identity 1 evidence

Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.

Data access & reproducibility

Record scopePublic release

ATL peptide ID: ATLPC0002790
Identity type: canonical sequence
ADMET endpoints: 3
Measurements: 40
Reference groups: 9
Release view: Public release

Analysis-ready files

Peptide record

TSV

Identity, sequence, profile-level fields, and current release view metadata.

Download record

Programmatic access

The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.

Open endpoint

GET /api/v1/peptides/ATLPC0002790

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0002790' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.

KRIVQRIKDFLR{nt:C6H5-C≡C-CO}{ct:Amid}

% cytotoxicity5 measurements · 5 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	50 %	Comparable	CEM-SS cells · CEM-SS cells	Not specified	Open
2	0 %	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open
3	0 %	Comparable	Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human	Not specified	Open
4	60 %	Comparable	Murine macrophage cells J774A.1 · Murine macrophage cells J774A.1 · mouse	Not specified	Open
5	10 %	Comparable	Murine macrophage cells J774A.1 · Murine macrophage cells J774A.1 · mouse	Not specified	Open

Cytotoxicity metric12 measurements · 12 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	40.5 μg/mL	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open
2	10.13 μg/mL	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open
3	84.2 μg/mL	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open
4	3.23 μg/mL	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open
5	10 μg/mL	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open
6	1.29 μg/mL	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open
7	38.73 μg/mL	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open
8	74.6 μg/mL	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open
9	5.97 μg/mL	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open
10	7.6 μg/mL	Comparable	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Not specified	Open

1–10 / 12

ATLPC0002790

Peptide developability profile

1. Sequence & peptidoform

Sequence interpretation

2. Structure & chemistry

Structure and chemistry interpretation

3. Physicochemical profile

Computed descriptors

Computed developability descriptors

4. Product context

Translational product context

5. Toxicity / Safety

Evidence summary

6. Evidence landscape

Evidence landscape and measurement index

7. Identity & reference map

Identity & reference map

8. Data access & reproducibility

Data access & reproducibility

Peptide record

Evidence table

Structured record